Board of Directors
Non-Executive Chairman - Dr Roger Aston(BSc (Hons), PhD)
Dr Aston has more than 20 years of experience in the pharmaceutical and biotech industries. Dr Aston was previously the Chief Executive Officer and a Director of Mayne Pharma Group Limited.
Prior to his position at Mayne Pharma, some of his previous positions have included CEO of Peptech Limited (Australia), Director of Cambridge Antibody Technology Limited (UK) and Chairman of Cambridge Drug Discovery Limited (UK – now Bio Focus plc).
Dr Aston was also founder and CEO of Biokine Technology Ltd (UK) prior to its acquisition by the Peptech Group. Dr Aston was also a director of pSivida Ltd. During the past 20 years of his career, Dr Aston has been closely involved in the development of many successful pharmaceutical and biotechnology companies.
Dr Aston has extensive experience including negotiating global licence agreements, overseeing product registration activities with the FDA, the establishment and implementation of guidelines and operating procedures for manufacturing and clinical trials, overseeing manufacturing of human and veterinary products, private and public fund raising activities and the introduction of corporate governance procedures.
Executive Vice Chairman - Mr. Peter Anastasiou(B.Psych)
Mr Anastasiou is a serial entrepreneur and investor with extensive experience in business both in Australia and overseas. Over the past 25 years, he has been credited with rebuilding a number of companies through the implementation of various corporate restructurings, acquisitions and solid financial management practices, with his most recent success being managing the restructuring of SABCO to ensure the future of this 100 year old iconic Australian company.
Mr Anastasiou’s involvement with Immuron commenced in May 2013 following his substantial underwriting support of the Company’s Renounceable Rights Issue, which was surpassed by his further funding support of the $9.66M (before costs) capital raising in February 2014 resulting in an ownership of approx. 15% of the Company via his associated investment funds.
Mr Anastasiou was the founding Chairman of the ACSI Group of Companies, which has owned and managed successful consumer companies such as SABCO, Britex Carpet care, Rug Doctor and Crystal Clear.
Mr Anastasiou also has a number of philanthropic interests including being a patron of the Identity Theatre for men, a prior board member and supporter of the Indigenous Eye Health Unit at Melbourne University, a supporter of the John Fawcett Foundation in Bali, and a founding investor and Director of Melbourne Victory Football Club.
Non-Executive Director - Mr Daniel Pollock(LL.B; Dip L.P)
Mr Pollock is a lawyer admitted in both Scotland and Australia and holding Practicing Certificates in both Jurisdictions. He is sole practitioner in his own legal firm based in Melbourne, Australia which operates internationally and specializes in commercial law.
Mr Pollock is Chairman and Company Secretary of Amaero Pty Ltd, a company established to commercialise laser based additive manufacturing emerging from Monash University.
He is also Executive Director and co-owner of Great Accommodation P/L a property management business operating in Victoria.
Mr Pollock has had historical involvement as a seed investor and Board member of a number of small unlisted companies. The most recent of these was an E-Pharmacy company where he was heavily involved in its commercial growth and ultimate sale to a large listed health services company.
Non-Executive Director - Mr. Stephen Anastasiou
(BSc (Hons), Grad. Dip MKTG, MBA)
Mr Anastasiou has over 20 years’ experience in general management, marketing and strategic planning within the healthcare industry.
His breadth of experience incorporates medical diagnostics, pharmaceuticals, hospital, dental and OTC products, with companies including the international pharmaceutical company Bristol - Myers Squibb.
While working with KPMG Peat Marwick as a management consultant, Mr. Anastasiou has previously led project teams in a diverse range of market development and strategic planning projects in both the public and private sector. He is also a director and shareholder of a number of unlisted private companies, covering a variety of industry sectors that include healthcare and funds management.
Mr Anastasiou’s companies have participated in several corporate transactions involving business units and brands of multinational and Australian companies
Non-Executive Director - Prof. Ravi Savarirayan
(MD (Melb.), BS (Adel.), FRACP, ARCPA (Hon.)
Victorian Clinical Genetics Services, Murdoch Childrens Research Institute and University of Melbourne Australia Ravi Savarirayan is consultant clinical geneticist at Victorian Clinical Genetics Services, Professorial fellow at the University of Melbourne, and research group leader (Musculoskeletal disease) at Murdoch Childrens Research Institute, Victoria, Australia.
Professor Savarirayan received his MBBS from the University of Adelaide, Australia in 1990 and became a Fellow of the Royal Australasian College of Physicians in 1997. He was certified as a specialist in Clinical Genetics by the Human Genetics Society of Australasia in 1998, and was awarded his Doctorate of Medicine from the University of Melbourne in 2004, for his thesis “Clinical and molecular studies in the Osteochondrodysplasias.” He was the youngest recipient of the Fulbright Professional Award for Australia in 1998, and took his fellowship up at University of California, Los Angeles (UCLA).
Professor Savarirayan is a founding member of the Skeletal Dysplasia Management Consortium and is the current Chair of the Advanced Training Committee in Clinical Genetics, Royal Australasian College of Physicians. He was the first Australian elected President of the International Skeletal Dysplasia Society, and has been invited to give plenary talks at major scientific conferences in North and South America, Asia, Europe, and Australasia.
Professor Savarirayan’s primary research focus is on inherited disorders of the skeleton causing short stature, arthritis and osteoporosis. He has published over 150 peer-reviewed articles, collaborating with researchers from over 40 countries. He serves on the editorial boards several prestigious journals, including Human Mutation, European Journal of Human Genetics, American Journal of Medical Genetics, and Journal of Medical Genetics.
His current clinical and research activities focus on the translation of genomic data into tangible and meaningful outcomes for individuals, families, and health care systems,and advocating for equal access and uptake of new genetic technologies and therapies for all.